According to the previous study, eIF5A2 (located at 3q26.2), has been significantly associated with the advanced stage of ovarian cancer and has been described as an adverse prognostic marker of survival in stage I non-small cell lung cancer patients and localized invasive bladder cancer [13, 15, 16]. This evidence concerns the gene EIF5A2 and non-small cell lung carcinoma.